1. Home
  2. SNCY vs TBPH Comparison

SNCY vs TBPH Comparison

Compare SNCY & TBPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sun Country Airlines Holdings Inc.

SNCY

Sun Country Airlines Holdings Inc.

HOLD

Current Price

$16.84

Market Cap

1.1B

ML Signal

HOLD

Logo Theravance Biopharma Inc.

TBPH

Theravance Biopharma Inc.

HOLD

Current Price

$14.76

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SNCY
TBPH
Founded
1982
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Air Freight/Delivery Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
1.0B
IPO Year
2021
2013

Fundamental Metrics

Financial Performance
Metric
SNCY
TBPH
Price
$16.84
$14.76
Analyst Decision
Buy
Strong Buy
Analyst Count
8
5
Target Price
$19.29
$18.50
AVG Volume (30 Days)
803.0K
830.5K
Earning Date
04-30-2026
03-19-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
279.13
EPS
0.96
2.06
Revenue
$1,126,769,000.00
$15,386,000.00
Revenue This Year
$9.52
$9.51
Revenue Next Year
$9.40
N/A
P/E Ratio
$16.56
$16.23
Revenue Growth
4.74
N/A
52 Week Low
$8.10
$7.90
52 Week High
$22.29
$21.03

Technical Indicators

Market Signals
Indicator
SNCY
TBPH
Relative Strength Index (RSI) 45.83 40.20
Support Level $10.77 $13.41
Resistance Level $18.28 $15.22
Average True Range (ATR) 0.74 0.44
MACD -0.07 0.14
Stochastic Oscillator 38.60 89.80

Price Performance

Historical Comparison
SNCY
TBPH

About SNCY Sun Country Airlines Holdings Inc.

Sun Country Airlines Holdings Inc operates low-cost air carriers. The business has two operating segments: Passenger and Cargo. The passenger segment has two internal passenger groups Scheduled service and Charter. The Cargo segment provides air cargo services. The majority of the revenue is from the passenger segment.

About TBPH Theravance Biopharma Inc.

Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

Share on Social Networks: